{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:37:52Z","timestamp":1792651072466,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00415-026-14152-x","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:40:29Z","timestamp":1792647629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prediction of short-term and long-term responses to cladribine in relapsing\u2013remitting multiple sclerosis: a Danish nationwide real-world study"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9482-1771","authenticated-orcid":false,"given":"Stephan","family":"Bramow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Pontieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Heick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Thormann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Sejb\u00e6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Vestergaard","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkadiusz","family":"Weglewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanga Hassan","family":"Qadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeppe Romme","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"M\u00e6rsk-M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine","family":"Zachariassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Stilund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik Boye","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Christina Hilt","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Sellebjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Soelberg","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Magyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Danish Multiple Sclerosis Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Heick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Isabel Figueira","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Thormann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Sellebjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeppe","family":"Romme Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"N\u00f8rregaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jette Lautrup","family":"Frederiksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie Richter","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Ingrid","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Blinkenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Soelberg","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke Marie","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Bramow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thor","family":"Chalmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria Papp","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Magyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Koch-Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Leif Munding","family":"Stilund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkadiusz","family":"Weglewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik Kahr","family":"Mathiesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik Boye","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egon","family":"Stenager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai Bang","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Langemark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Broksgaard","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia Mubder","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1sta Milthers","family":"The\u00f3d\u00f3rsd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle Hvilsted","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Demirovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt Laszlo","family":"Ill\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homayoun","family":"Roshanisefat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Falah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin","family":"Asgari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afzal","family":"Gardezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepehr","family":"Mamoei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thor","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Sejb\u00e6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Urbonaviciute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael","family":"Barzinji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"M\u00e6rsk-M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline Winther","family":"T\u00f8rring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina Bacher","family":"Svendsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Vestergaard","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgi P.","family":"Sirakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivagini","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsvetomir","family":"Asenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Kristian","family":"Storr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena Christina","family":"Roug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika Katarzyna","family":"G\u00f3ra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Ashna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"14152_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106600","volume":"103","author":"A Albanese","year":"2025","unstructured":"Albanese A, Schiavetti I, Sormani MP (2025) Real-world experience with cladribine in the two years since treatment start: a systematic review and meta-analysis. Mult Scler Relat Disord 103:106600","journal-title":"Mult Scler Relat Disord"},{"key":"14152_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106885","volume":"106","author":"H Butzkueven","year":"2026","unstructured":"Butzkueven H, Farr P, Ozakbas S, Boz C, Kalincik T, Taylor L, Van Der Walt A, Alroughani R, Buzzard K, Skibina O, Lechner-Scott J, Laureys G, Terzi M, Van Pesch V, Grand-Maison F, Barnett M, Kermode A, Menoyo JLS, Rojas J, Willekens B, Foschi M, Ramo-Tello C, Skromne E, Dirks P, Rouzic EM-L, Spelman T (2026) Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: an MSBase registry sub-study. Mult Scler Relat Disord 106:106885","journal-title":"Mult Scler Relat Disord"},{"key":"14152_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ana.26913","volume":"96","author":"M Calabrese","year":"2024","unstructured":"Calabrese M, Preziosa P, Scalfari A, Colato E, Marastoni D, Absinta M, Battaglini M, De Stefano N, Di Filippo M, Hametner S, Howell OW, Inglese M, Lassmann H, Martin R, Nicholas R, Reynolds R, Rocca MA, Tamanti A, Vercellino M, Villar LM, Filippi M, Magliozzi R (2024) Determinants and biomarkers of progression independent of relapses in multiple sclerosis. Ann Neurol 96:1\u201320","journal-title":"Ann Neurol"},{"key":"14152_CR4","volume":"1","author":"MG Celani","year":"2026","unstructured":"Celani MG, Orso M, Melis M, Ercolani MV, Cantisani TA (2026) Cladribine for people with multiple sclerosis. Cochrane Database Syst Rev 1:CD013524","journal-title":"Cochrane Database Syst Rev"},{"key":"14152_CR5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210305","volume":"104","author":"A Cobo-Calvo","year":"2025","unstructured":"Cobo-Calvo A, Carbonell-Mirabent P, Tur C, Otero-Romero S, Carvajal R, Arrambide G, Ari\u00f1o H, Auger C, Villacieros-\u00c1lvarez J, Bollo L, Castill\u00f3 J, Comabella M, Espejo C, Fern\u00e1ndez V, Guio-S\u00e1nchez C, Galan I, La Puma D, Midaglia LS, Mongay-Ochoa N, Vilaseca A, Arevalo Navines MJ, Nos C, Pappolla A, Rio J, Rodriguez Acevedo B, Zabalza A, Vidal-Jordana A, Pareto D, Sastre-Garriga J, Rovira \u00c0, Montalban X, Tintore M (2025) Age-related disability outcomes after a first demyelinating event. Neurology 104:e210305","journal-title":"Neurology"},{"key":"14152_CR6","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1007\/s00415-012-6775-0","volume":"260","author":"G Comi","year":"2013","unstructured":"Comi G, Cook SD, Giovannoni G, Rammohan K, Rieckmann P, Sorensen PS, Vermersch P, Hamlett AC, Viglietta V, Greenberg SJ (2013) MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol 260:1136\u20131146","journal-title":"J Neurol"},{"key":"14152_CR7","doi-asserted-by":"publisher","DOI":"10.1177\/175628561775336","author":"C Giancarlo","year":"2018","unstructured":"Giancarlo C, Stuart C, Kottil R, Per Soelberg S, Patrick V, Abidemi KA, Fernando D, Gavin G (2018) Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis\u202f: the CLARITY Extension study. Sage J. https:\/\/doi.org\/10.1177\/175628561775336","journal-title":"Sage J"},{"key":"14152_CR8","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, S\u00f8rensen PS, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 362:416\u2013426","journal-title":"N Engl J Med"},{"key":"14152_CR9","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.1007\/s12325-021-01865-w","volume":"38","author":"G Giovannoni","year":"2021","unstructured":"Giovannoni G, Comi G, Rammohan K, Rieckmann P, Dangond F, Keller B, Jack D, Vermersch P (2021) Long-term disease stability assessed by the expanded disability status scale in patients treated with cladribine tablets 3.5 mg\/kg for relapsing multiple sclerosis: an exploratory post hoc analysis of the CLARITY and CLARITY extension studies. Adv Ther 38:4975\u20134985","journal-title":"Adv Ther"},{"key":"14152_CR10","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1177\/13524585211049392","volume":"28","author":"G Giovannoni","year":"2022","unstructured":"Giovannoni G, Singer BA, Issard D, Jack D, Vermersch P (2022) Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: the CLARITY extension study. Mult Scler 28:1219\u20131228","journal-title":"Mult Scler"},{"key":"14152_CR11","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1177\/1352458517727603","volume":"24","author":"G Giovannoni","year":"2018","unstructured":"Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, Dangond F, Adeniji AK, Vermersch P (2018) Safety and efficacy of cladribine tablets in patients with relapsing\u2013remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler J 24:1594\u20131604","journal-title":"Mult Scler J"},{"key":"14152_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S1474-4422(11)70023-0","volume":"10","author":"GP Giovannoni","year":"2011","unstructured":"Giovannoni GP, Cook SP, Rammohan KP, Rieckmann PMD, S\u00f8rensen PSP, Vermersch PP, Hamlett AP, Viglietta VMD, Greenberg SMD (2011) Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol 10:329\u2013337","journal-title":"Lancet Neurol"},{"key":"14152_CR13","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200415","volume":"12","author":"T Guerra","year":"2025","unstructured":"Guerra T, Copetti M, Zanetta C, Patti F, Chisari CG, Barbuti E, Portaccio E, Foschi M, Conte A, Ferraro D, Cocco EE, Fantozzi R, Maniscalco GT, Salemi G, Tortorella C, Paolicelli D, Filippi M, Amato MP, Trojano M, Iaffaldano P, Italian Multiple S, Related Disorders R (2025) The Italian Multiple Sclerosis Register Experience With Cladribine: Impact on Relapses, PIRA, and Treatment Sequencing Strategies Evaluation. Neurol Neuroimmunol Neuroinflamm 12:e200415","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"14152_CR14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2165\/00003088-199732020-00003","volume":"32","author":"J Liliemark","year":"1997","unstructured":"Liliemark J (1997) The clinical pharmacokinetics of cladribine. Clin Pharmacokinet 32:120\u2013131","journal-title":"Clin Pharmacokinet"},{"key":"14152_CR15","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251360047","volume":"18","author":"M Lucchini","year":"2025","unstructured":"Lucchini M, Borriello G, Haggiag S, Nicoletti CG, Fantozzi R, Buscarinu MC, Ferrazzano G, Cortese A, Marinelli F, Monteleone F, Centonze D, Conte A, Ferraro E, Gasperini C, Marfia GA, Pozzilli C, Salvetti M, Barbuti E, Bellucci G, Bianco A, Carlomagno V, Cruciani A, De Giglio L, Dionisi C, Ianniello A, Malimpensa L, Nasello M, Nociti V, Prosperini L, Tortorella C, Mirabella M (2025) Real-world experience with cladribine tablets in people with multiple sclerosis: effectiveness data from a multicenter Italian study. Ther Adv Neurol Disord 18:17562864251360047","journal-title":"Ther Adv Neurol Disord"},{"key":"14152_CR16","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1093\/brain\/awy151","volume":"141","author":"J Machado-Santos","year":"2018","unstructured":"Machado-Santos J, Saji E, Troscher AR, Paunovic M, Liblau R, Gabriely G, Bien CG, Bauer J, Lassmann H (2018) The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells. Brain 141:2066\u20132082","journal-title":"Brain"},{"key":"14152_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1921","volume":"11","author":"M Magyari","year":"2021","unstructured":"Magyari M, Joensen H, Laursen B, Koch-Henriksen N (2021) The Danish multiple sclerosis registry. Brain Behav 11:e01921","journal-title":"Brain Behav"},{"key":"14152_CR18","first-page":"1232","volume":"80","author":"J M\u00fcller","year":"2023","unstructured":"M\u00fcller J, Cagol A, Lorscheider J, Tsagkas C, Benkert P, Yaldizli \u00d6, Kuhle J, Derfuss T, Sormani MP, Thompson A, Granziera C, Kappos L (2023) Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review. Archives of neurology (Chicago) 80:1232\u20131245","journal-title":"Archives of neurology (Chicago)"},{"key":"14152_CR19","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1001\/jamaneurol.2025.0495","volume":"82","author":"J M\u00fcller","year":"2025","unstructured":"M\u00fcller J, Sharmin S, Lorscheider J, Ozakbas S, Karabudak R, Horakova D, Weinstock-Guttman B, Shaygannejad V, Etemadifar M, Alroughani R, Patti F, Eichau S, Prat A, Lugaresi A, Tomassini V, Kermode AG, Amato MP, Turkoglu R, Altintas A, Buzzard K, Soysal A, van der Walt A, Butzkueven H, Blanco Y, Gerlach O, Khoury SJ, Barnett M, John N, Lechner-Scott J, Foschi M, Surcinelli A, van Pesch V, Prevost J, Sa MJ, Maimone D, D\u2019Hooghe M, Hughes S, Hodgkinson S, McGuigan C, Cartechini E, Taylor B, Spitaleri D, Slee M, McCombe P, Yamout B, Benkert P, Kuhle J, Kappos L, Roos I, Kalincik T, Havrdova EK, Girard M, Duquette P, Fabis-Pedrini M, Carroll WM, Skibina O, Gouider R, Mrabet S, Ramo-Tello C, Solaro C, Habek M, Van Wijmeersch B, Ampapa R, Macdonell R, Oreja-Guevara C, de Gans K, Laureys G, Oh J, Garber J, Gray O, Ag\u00fcera-Morales E, Sanchez-Menoyo JL, Castillo-Trivi\u00f1o T, Grigoriadis N, Petersen T, Hardy TA, Vucic S, Reddel S, Ramanathan S, Al-Asmi A, Simu M, Baghbanian SM, Poehlau D, Al-Harbi T, Rojas JI, Deri N, Lalive P, Cambron M, Csepany T, Shuey N, Willekens B, Shaw C, Decoo D, Massey J, Yaldizli \u00d6, Derfuss T, Granziera C (2025) Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis. JAMA Neurol 82:614\u2013625","journal-title":"JAMA Neurol"},{"key":"14152_CR20","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419836913","volume":"12","author":"PS Sorensen","year":"2019","unstructured":"Sorensen PS, Sellebjerg F (2019) Pulsed immune reconstitution therapy in multiple sclerosis. Ther Adv Neurol Disord 12:1756286419836913","journal-title":"Ther Adv Neurol Disord"},{"key":"14152_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106724","volume":"103","author":"I Rauma","year":"2025","unstructured":"Rauma I, Viitala M, Soilu-Hanninen M, Atula S, Laakso S, Kuusisto H, Niiranen M, Ryytty M, Manni V (2025) The real-world efficacy of Cladribine tablets and treatment persistence in people with highly active relapsing multiple sclerosis in Finland - A follow-up study after four years of observation. Mult Scler Relat Disord 103:106724","journal-title":"Mult Scler Relat Disord"},{"key":"14152_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/13524585251342727","author":"BE R\u00f8d","year":"2025","unstructured":"R\u00f8d BE, H\u00f8gest\u00f8l EA, Torkildsen \u00d8, Bj\u00f8rnevik K, Gran JM, \u00d8ver\u00e5s MH, K\u00f6nig M, Myhr K-M, Wergeland S, Nygaard GO (2025) Comparative effectiveness of rituximab and cladribine in relapsing\u2013remitting multiple sclerosis: a target trial emulation. Mult Scler J. https:\/\/doi.org\/10.1177\/13524585251342727","journal-title":"Mult Scler J"},{"key":"14152_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/13524585221137502","volume":"29","author":"T Spelman","year":"2023","unstructured":"Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, Laureys G, Kalincik T, Van Der Walt A, Yamout B, Lechner-Scott J, Soysal A, Kuhle J, Sanchez-Menoyo JL, Blanco Morgado Y, Spitaleri D, van Pesch V, Horakova D, Ampapa R, Patti F, Macdonell R, Al-Asmi A, Gerlach O, Oh J, Altintas A, Tundia N, Wong SL, Butzkueven H (2023) Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry. Mult Scler 29:221\u2013235","journal-title":"Mult Scler"},{"key":"14152_CR24","first-page":"1330","volume":"93","author":"C Zhu","year":"2022","unstructured":"Zhu C, Zhou Z, Roos I, Merlo D, Kalincik T, Ozakbas S, Skibina O, Kuhle J, Hodgkinson S, Boz C, Alroughani R, Lechner-Scott J, Barnett M, Izquierdo G, Prat A, Horakova D, Kubala Havrdova E, Macdonell R, Patti F, Khoury SJ, Slee M, Karabudak R, Onofrj M, Van Pesch V, Prevost J, Monif M, Jokubaitis V, van der Walt A, Butzkueven H, Group MSS (2022) Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis. J Neurol Neurosurg Psychiatry 93:1330\u20131337","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14152-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14152-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14152-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:40:31Z","timestamp":1792647631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14152-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["14152"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-14152-x","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"27 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Stephan Bramow has received speaking honoraria or support for congress participation from Roche, Novartis, Merck and Sanofi. Luigi Pontieri has received speaking honoraria from Sanofi. Alex Heick served on scientific advisory boards for Biogen, Sanofi-Genzyme, Novartis, Janssen and Merck, received honoraria for lecturing has been received from Biogen, Merck, Novartis and Sanofi, and received support for congress participation from Biogen, Sanofi-Genzyme, Teva, Roche, Merck, Novartis, Bayer, Schering, Pfizer and Janssen. Anja Thormann has nothing to disclose. Tobias Sejb\u00e6k has served in scientific advisory board for Biogen, Merck, Novartis, Roche and Sanofi, and has received honoraria for lecturing from Biogen, Merck, Novartis, Roche, Sanofi. Peter Vestergaard Rasmussen has served on scientific advisory boards for, served as consultant for, received support for congress participation or received speaker honoraria from Alexion, Biogen, Bristol Myers Squibb, Merck, Novartis, Roche and Sanofi Genzyme. Arkadiusz Weglewski has served on scientific advisory boards for Merck, Roche, Sanofi, has received conference travel support from Biogen, Merck, Roche, Sanofi, Novartis and speaker honoraria from Roche, Merck and Sanofi. Shanga Hassan Quadir has nothing to disclose. Jeppe Romme Christensen has nothing to disclose. Camilla M\u00e6rsk-M\u00f8ller has nothing to disclose. Katrine Zachariassen has nothing to disclose. Jakob Sch\u00e4fer has served on advisory boards for Merck, Roche, Novartis and Sanofi, received speaker honoraria from Novartis and Merck and travel compensation for congress participation from Merck, Roche, and Sanofi. Morten Stilund has served on scientific advisory boards for, received support for congress participation or received speaker honoraria from Biogen, Merck, Novartis, Roche and Sanofi Genzyme. Henrik Boye Jensen has served as advisory board member for Merck and Roche and has received speaker honoraria from Biogen and Novartis. Claudia Hilt has served on scientific advisory boards or received support for congress participation from Biogen, Merck, Novartis, Roche and Sanofi. Matthias Kant has nothing to disclose. Finn Sellebjerg has served on scientific advisory boards for, served as consultant for, received support for congress participation or received speaker honoraria from Biogen, Lundbeck, Merck, Neuraxpharm, Novartis, Roche and Sanofi. His laboratory has received research support from Biogen, Merck, Novartis, Roche and Sanofi. Finn Sellebjerg is section editor on Multiple Sclerosis and Related Disorders. Per Soelberg S\u00f8rensen has received personal compensation for consultations, serving on scientific advisory boards, steering committees, independent data monitoring committees from Biogen, Merck and Novartis. Melinda Magyari has served on scientific advisory boards, served as a consultant, received support for congress participation, or received speaker honoraria from Roche, Sanofi, Biogen, Merck, Novartis, Bristol Myers Squibb, Medscape, Alexion, and Moderna. The Danish MS Registry has received research support from and\/or has had other forms of contact with Biogen, Merck, Novartis, Roche, Sanofi, and Bristol Myers Squibb.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"According to Danish law, retrospective registry-based studies using anonymised or pseudonymised administrative and health data do not require ethical approval from the National Committee on Health Research Ethics. The study was approved by the Danish Data Protection Agency through the joint notification of the Capital Region of Denmark.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"676"}}